BioPlan Associates

Activities: Media

Trending Articles

  1. Roche acquires clinical-stage biopharmaceutical company Poseida Therapeutics Through the merger, Roche will acquire Poseida's allogeneic CAR-T cell therapy portfolio, including pre-clinical and clinical-stage iterations for a range of conditions
  2. Aurobindo Pharma signs $25m respiratory drug development and commercialisation deal with global pharma company The companies will co-develop and commercialise respiratory therapeutics, diversifying Aurobindo's current portfolio
  3. IMed Consultancy helps Toby Orthopaedics navigate UK regulations Regulatory consultancy ensures compliance and confidence for Miami-based company
  4. Vetter strengthens senior management team for growth Three new managing directors to support global sustainable development
  5. Merck's Welireg approved for cancers associated with von Hippel-Lindau disease in China The once-daily drug is the first HIF-2α to be approved in China, exhibiting a 49% objective response rate (ORR)

Upcoming event

CPhI Middle East

10–12 December 2024 | Conference | Riyadh, Saudi Arabia See all

Related Content

Media

Trends and opportunities in biopharmaceutical product development and manufacturing

The biopharmaceutical industry and its bioprocessing sector are healthy and continue to grow in size/revenue, breadth, importance and diversity. Worldwide sales of biopharmaceuticals are now more than $300 billion, increasing at an annual rate of about 12% annually. This growth has been relatively consistent during the past 15+ years, which is why the segment is attractive to investors, explains Eric Langer, President and Managing Partner, BioPlan Associates
Subscribe now